Q175 Mouse

Charles River conducts contract studies in Q175 knock-in mice to test the efficacy of novel therapeutics for treating Huntington’s disease. The Q175 mouse shows robust, gene dose-dependent, progressive and early-onset alterations in the validated endpoint assays. All studies can be customized according to client needs.

The Q175 knock-in mouse contains human mHtt allele with the expanded CAG repeat (~179 repeats) within the native mouse huntingtin gene. Thus, this animal model is representative of Huntington’s disease in humans from a genetic aspect. Both homo- and heterozygous Q175 mice exhibit first signs of motor symptoms early, from 3-4 months of age, and behavioral deficits are accompanied by marked brain atrophy and brain metabolite changes by 8 months.

Study Components

  • Motor deficits
    • Open field test
    • Rear climbing
  • Cognitive deficits
    • Procedural two-choice swim test
  • Neurological index
  • Imaging
    • In vivo MRI for brain volumetry (whole brain, cortex, striatum)
    • In vivo 1H-MRS of the striatum metabolic profile
  • Biomarkers
  • Various options in mRNA and protein detection assays

Testing / Validation Data

Click below to see a sample data set.

You may also be interested in...

Imaging Services

Our range of imaging modalities can dramatically increase the efficacy and significantly enhance the value of your in vivo study.